Search research articles
Contact Us
Filters
Showing results (171-180 of 201) with videos related to
Page
of 21
Sort By:
Cancer Research
|
April 22, 2017
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi, Laura Schubert, Uwe Rix, et al.
Oncotarget
|
October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
Lu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Cancer
|
October 3, 2014
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
Liza C Villaruz, Mark A Socinski, Shira Abberbock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Alison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Cancer Medicine
|
November 21, 2019
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses
Theresa A Boyle, Gwendolyn P Quinn, Matthew B Schabath, et al.
Cancer Research
|
October 30, 2025
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer
Hitendra S Solanki, Harshit Shah, Denis Imbody, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
December 27, 2019
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance
Theresa A Boyle, Farah K Khalil, Mari Mino-Kenudson, et al.
Immunity
|
April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling
Eslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 201) with videos related to
Sort By:
Page
of 21
Cancer Research
|
April 22, 2017
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi, Laura Schubert, Uwe Rix, et al.
Oncotarget
|
October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
Lu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Cancer
|
October 3, 2014
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
Liza C Villaruz, Mark A Socinski, Shira Abberbock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Alison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in <i>EGFR</i>-mutant NSCLC Following Resistance to Initial <i>EGFR</i> Therapy (ETCTN 9903)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Cancer Medicine
|
November 21, 2019
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses
Theresa A Boyle, Gwendolyn P Quinn, Matthew B Schabath, et al.
Cancer Research
|
October 30, 2025
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer
Hitendra S Solanki, Harshit Shah, Denis Imbody, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
December 27, 2019
Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance
Theresa A Boyle, Farah K Khalil, Mari Mino-Kenudson, et al.
Immunity
|
April 16, 2020
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling
Eslam Mohamed, Rosa A Sierra, Jimena Trillo-Tinoco, et al.
Page
of 21